• Halozyme Therapeutics average return on tangible equity for 2024 was -60.42, a 107.77% increase from 2023.
• Halozyme Therapeutics average return on tangible equity for 2023 was -29.08, a 87.28% increase from 2022.
• Halozyme Therapeutics average return on tangible equity for 2022 was -228.62, a 205.46% decline from 2021.

Return on tangible equity can be defined as the amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity.